Regeneron Pharmaceuticals, Inc. (REGN)
781.49
-11.77
(-1.48%)
USD |
NASDAQ |
Sep 11, 16:00
781.00
-0.49
(-0.06%)
After-Hours: 20:00
Regeneron Pharmaceuticals Price to Book Value : 2.548 for Sept. 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 2.548 |
| September 10, 2026 | 2.586 |
| September 09, 2026 | 2.634 |
| September 08, 2026 | 2.642 |
| September 04, 2026 | 2.699 |
| September 03, 2026 | 2.750 |
| September 02, 2026 | 2.778 |
| September 01, 2026 | 2.686 |
| August 31, 2026 | 2.606 |
| August 28, 2026 | 2.590 |
| August 27, 2026 | 2.634 |
| August 26, 2026 | 2.657 |
| August 25, 2026 | 2.718 |
| August 24, 2026 | 2.702 |
| August 21, 2026 | 2.720 |
| August 20, 2026 | 2.695 |
| August 19, 2026 | 2.742 |
| August 18, 2026 | 2.642 |
| August 17, 2026 | 2.628 |
| August 14, 2026 | 2.620 |
| August 13, 2026 | 2.628 |
| August 12, 2026 | 2.602 |
| August 11, 2026 | 2.599 |
| August 10, 2026 | 2.635 |
| August 07, 2026 | 2.558 |
| Date | Value |
|---|---|
| August 06, 2026 | 2.518 |
| August 05, 2026 | 2.506 |
| August 04, 2026 | 2.480 |
| August 03, 2026 | 2.476 |
| July 31, 2026 | 2.487 |
| July 30, 2026 | 2.408 |
| July 29, 2026 | 2.268 |
| July 28, 2026 | 2.267 |
| July 27, 2026 | 2.175 |
| July 24, 2026 | 2.139 |
| July 23, 2026 | 2.126 |
| July 22, 2026 | 2.123 |
| July 21, 2026 | 2.202 |
| July 20, 2026 | 2.192 |
| July 17, 2026 | 2.206 |
| July 16, 2026 | 2.214 |
| July 15, 2026 | 2.166 |
| July 14, 2026 | 2.139 |
| July 13, 2026 | 2.162 |
| July 10, 2026 | 2.167 |
| July 09, 2026 | 2.178 |
| July 08, 2026 | 2.161 |
| July 07, 2026 | 2.205 |
| July 06, 2026 | 2.119 |
| July 02, 2026 | 2.133 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 24.56 |
| AbbVie, Inc. | -- |
| Gilead Sciences, Inc. | 15.08 |
| Amgen, Inc. | 17.45 |
| Biogen, Inc. | 1.702 |
Price to Book Value Related Metrics
| PE Ratio | 19.31 |
| PS Ratio | 5.388 |
| PEG Ratio | 9.885 |
| Price to Free Cash Flow | 23.41 |
| Price | 781.49 |
| Earnings Yield | 5.18% |
| Market Cap | 80.81B |
| PEGY Ratio | 7.957 |
| Operating PE Ratio | 20.05 |
| Normalized PE Ratio | 18.22 |